Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Tumor Virus Infections D014412 8 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pleurisy D010998 20 associated lipids
Burns D002056 34 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Infertility, Male D007248 11 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Brain Injuries D001930 4 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Pulmonary Edema D011654 23 associated lipids
Coronary Disease D003327 70 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Pancreatitis D010195 10 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Rhinitis D012220 10 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Melanoma D008545 69 associated lipids
Asthma D001249 52 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Peritonitis D010538 38 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Spasm D013035 5 associated lipids
Lymphoma D008223 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Arteriosclerosis D001161 86 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Thalassemia D013789 8 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Glomerulonephritis D005921 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Psoriasis D011565 47 associated lipids
Brain Edema D001929 20 associated lipids
Leukopenia D007970 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Burns, Inhalation D002059 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Fetal Weight D020567 12 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemia D007511 18 associated lipids
Colonic Diseases D003108 5 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Page CP et al. An in vivo model for studying platelet aggregation and disaggregation. 1982 Thromb. Haemost. pmid:7051409
Mencia-Huerta JM et al. Biosynthesis of platelet-activating factor (PAF)acether). III. Formation of PAF-acether from synthetic substrates by stimulated murine macrophages. 1982 J. Immunol. pmid:7086143
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Chilton FH et al. Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. 1982 J. Biol. Chem. pmid:6802816
Vargaftig BB et al. Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. 1982 Thromb. Haemost. pmid:7135345
Sancho J et al. The effect of the injection of a synthetic platelet-activating factor (PAF-acether) on the fate of IgG aggregates in mice. 1982 Immunology pmid:7141463
Sybertz EJ et al. Studies on the interactions of acetyl glycerol ether phosphoryl choline with the sympathetic nervous system in rats. 1982 J. Pharmacol. Exp. Ther. pmid:7143227
Cabot MC et al. Metabolism of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by cell cultures. 1982 Life Sci. pmid:7162357
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Morgat JL et al. Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. 1982 Agents Actions pmid:7164942
Convert O et al. 1H NMR of PAF-acether: influence of solvent on its structure. 1982 Agents Actions pmid:7164943
Borrel MC et al. Additional techniques for the total synthesis of PAF-acether. 1982 Agents Actions pmid:7164944
Benveniste J et al. Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. 1982 Agents Actions pmid:7164945
Roubin R et al. Release of platelet-activating factor (PAF-acether) and leukotrienes C and D from inflammatory macrophages. 1982 Eur. J. Immunol. pmid:6122581
O'Flaherty JT Lipid mediators of inflammation and allergy. 1982 Lab. Invest. pmid:6126615
Pinckard RN The "new" chemical mediators of inflammation. 1982 Monogr Pathol pmid:6126808
Robeva R et al. [Changes in blood coagulation in glomerulonephritis]. 1982 Vutr Boles pmid:6219496
Chignard M et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. 1982 Eur. J. Pharmacol. pmid:6804248
Shukla SD and Hanahan DJ AGEPC (platelet activating factor) induced stimulation of rabbit platelets: effects on phosphatidylinositol, di- and triphosphoinositides and phosphatidic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6288030
Isobe J and Mizuno A Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. 1982 Tokushima J. Exp. Med. pmid:7170716
Ingraham LM et al. Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. 1982 Blood pmid:6282362
Valone FH et al. Specific binding of phospholipid platelet-activating factor by human platelets. 1982 J. Immunol. pmid:6286773
Czarneztki BM Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release. 1982 Chem. Phys. Lipids pmid:6814773
Yasaka T et al. Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). 1982 J. Immunol. pmid:6278021
Morgan WK et al. Byssinosis: some unanswered questions. 1982 Am. Rev. Respir. Dis. pmid:6808880
Miller OV et al. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence. 1982 Biochim. Biophys. Acta pmid:6285985
Bruni A and Palatini P Biological and pharmacological properties of phospholipids. 1982 Prog Med Chem pmid:6758038
Masugi F et al. [Platelet-activating factor and antihypertensive polar renomedullary lipid: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine]. 1982 Tanpakushitsu Kakusan Koso pmid:6758041
Modiano A and Belisario A [Recent information on PAF (Platelet Activating Factor) in hemocoagulative and immuno-allergic processes]. 1982 G Clin Med pmid:6762313
Marcus AJ et al. Arachidonic acid metabolism in endothelial cells and platelets. 1982 Ann. N. Y. Acad. Sci. pmid:6762834
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Camussi G et al. Release of platelet-activating factor from HL-60 human leukemic cells following macrophage-like differentiation. 1982 Blood pmid:6947829
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Smith RJ and Bowman BJ Stimulation of human neutrophil degranulation with 1-O-octadecyl-2-O-acetyl-SN-glyceryl-3-phosphorylcholine: modulation by inhibitors of arachidonic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6803804
De Clerck F and David JL Pharmacological control of platelet and red blood cell function in the microcirculation. 1981 Nov-Dec J. Cardiovasc. Pharmacol. pmid:6173539
Camussi G et al. Immune-induced leucopenia. A role for the aggregation of polymorphonuclear neutrophils in systemic lupus erythematosus (SLE). 1981 Jul-Sep Minerva Nefrol pmid:7329598
Camussi G et al. In vitro spasmogenic effect of platelet-activating factor on rabbit lung tissue. 1981 Jul-Sep Panminerva Med pmid:7335369
Brown JE and Thuy LP The binding of bovine platelet aggregating factor to human platelets. 1981 Apr 1-15 Thromb. Res. pmid:7292446
O'Flaherty JT et al. Neutrophil-degranulating action of 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid and 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. Comparison with other degranulating agents. 1981 Am. J. Pathol. pmid:6274199
Shaw JO et al. Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). 1981 Biochim. Biophys. Acta pmid:7213765
McManus LM et al. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. 1981 J. Clin. Invest. pmid:7204562
Mencia-Huerta JM et al. Is platelet-activating factor (PAF-acether) synthesis by murine peritoneal cells (PC) a two-step process? 1981 Agents Actions pmid:7053072
Camussi G et al. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. 1981 Immunology pmid:6161885
Renooij W and Snyder F Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. 1981 Biochim. Biophys. Acta pmid:6260215
Mencia-Huerta JM and Benveniste J Platelet-activating factor (PAF-acether) and macrophages. II. Phagocytosis-associated release of PAF-acether from rat peritoneal macrophages. 1981 Cell. Immunol. pmid:6260384
Shaw JO et al. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). 1981 J. Immunol. pmid:6267133
Slauson DO and Sanchez-Vizcaino JM Leukocyte-dependent platelet vasoactive amine release and immune complex deposition in African swine fever. 1981 Vet. Pathol. pmid:6170156
O'Donnell MC and Fiedel BA Histamine secretion from human leucocytes stimulated by basophil-derived platelet-activating factor. 1981 Scand. J. Immunol. pmid:6171870
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Metcalfe DD et al. The mast cell. 1981 Crit. Rev. Immunol. pmid:6178551
Satouchi K et al. Modification of the polar head group of acetyl glyceryl ether phosphorylcholine and subsequent effects upon platelet activation. 1981 J. Biol. Chem. pmid:7217088
O'Flaherty JT et al. 1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. 1981 Am. J. Pathol. pmid:7223864
O'Flaherty JT et al. Evidence for 5, 12-dihydroxy-6,8,10,14-eicosatetraenoate as a mediator of human neutrophil aggregation. 1981 Biochem. Biophys. Res. Commun. pmid:6277309
Hanahan DJ et al. Potent platelet stimulating activity of enantiomers of acetyl glyceryl ether phosphorylcholine and its methoxy analogues. 1981 Biochem. Biophys. Res. Commun. pmid:7236259
Cox CP et al. The presence of platelet-activating factor (PAF) in normal human mixed saliva. 1981 J. Immunol. pmid:7240750
O'Donnell MC et al. Platelet activating factor: an inhibitor of neutrophil activation? 1981 Clin. Exp. Immunol. pmid:7249391
Findlay SR et al. Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. 1981 Am. J. Physiol. pmid:7282914
Demopoulos CA et al. Intravascular pathobiology of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF). I. Intravenous infusion in guinea pigs. 1981 Immunol. Lett. pmid:7287060
Halonen M et al. Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit. 1981 Am. Rev. Respir. Dis. pmid:7294504
Wykle RL et al. Stereospecific activity of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine and comparison of analogs in the degranulation of platelets and neutrophils. 1981 Biochem. Biophys. Res. Commun. pmid:7295320
O'Flaherty JT et al. Neutrophil responses to platelet-activating factor. 1981 Inflammation pmid:7298160
Blank ML et al. In vivo metabolism of a new class of biologically active phospholipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipid. 1981 Life Sci. pmid:7300575
Satouchi K et al. Influence of alkyl ether chain length of acetyl glyceryl ether phosphorylcholine and its ethanolamine analog on biological activity toward rabbit platelets. 1981 Arch. Biochem. Biophys. pmid:7305392
Gil MG et al. Inhibition of phospholipid methyltransferase during zymosan induced secretion of platelet-activating factor in human polymorphonuclear leukocytes. 1981 Biochem. Biophys. Res. Commun. pmid:7306113
Pinckard RN et al. Acetyl glyceryl ether phosphorylcholine: platelet-activating factor. 1981 Int. Arch. Allergy Appl. Immunol. pmid:7309256
Czarnetzki BM and Muramatsu T Saturated and unsaturated 1-O-alkyl-2-O-acetoyl-sn-glycero-3-phosphocholines derived from ratfish liver oil: effect on human leukocyte migration. 1981 Chem. Phys. Lipids pmid:7318048
Czarnetzki BM and Benveniste J Effect of 1-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on leukocytes I. Analysis of the in vitro migration of human neutrophils. 1981 Chem. Phys. Lipids pmid:7318049
Bonnet J et al. Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. 1981 Agents Actions pmid:7340441
Denjean A et al. Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons. 1981 Agents Actions pmid:7340444
Marcus AJ et al. Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro. 1981 Blood pmid:6457658
Deguchi K et al. [Blood platelet aggregation]. 1981 Nippon Rinsho pmid:6461781
O'Flaherty JT et al. Role of extracellular calcium and neutrophil degranulation responses to 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. 1981 Am. J. Pathol. pmid:6271016
Lee TC et al. 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) stimulates calcium influx in rabbit platelets. 1981 Biochem. Biophys. Res. Commun. pmid:6797422
Vargaftig BB and Ferreira SH Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. 1981 Braz. J. Med. Biol. Res. pmid:6802210
Perret BA et al. Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. 1981 Agents Actions pmid:6803540
Mencia-Huerta JM et al. Release of a slow-reacting substance from rabbit platelets. 1981 J. Clin. Invest. pmid:6119324
Furlan M et al. Binding of colloidal gold granules, coated with bovine factor VIII, to human platelet membranes. 1981 Br. J. Haematol. pmid:6786321
Chap H et al. Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. 1981 Nature pmid:7453828
Stimler NP et al. Anaphylactic actions of platelet-activating factor. 1981 Am. J. Pathol. pmid:6975043
Benveniste J et al. Platelet-activating factor (PAF-acether): molecular aspects of its release and pharmacological actions. 1981 Int. Arch. Allergy Appl. Immunol. pmid:7030966
Czarnetzki BM and Benveniste J Effect of synthetic PAF-acether on human neutrophil function. 1981 Agents Actions pmid:7041568
Camussi G et al. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). 1981 Agents Actions pmid:7041569
Vargaftig BB et al. Present concepts on the mechanisms of platelet aggregation. 1981 Biochem. Pharmacol. pmid:7011325
Colwell JA Studies on the pathogenesis of diabetic vascular disease. 1981 J S C Med Assoc pmid:7022022
Wintroub BU and Soter NA Biology of the mast cell and its role in cutaneous inflammation. 1981 Springer Semin. Immunopathol. pmid:7022722
Vargaftig BB et al. Background and present status of research on platelet-activating factor (PAF-acether). 1981 Ann. N. Y. Acad. Sci. pmid:7023317
Heymans F et al. New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures. 1981 Biochim. Biophys. Acta pmid:7306563
Karpatkin S et al. Role of platelets in tumor cell metastases. 1981 Ann. N. Y. Acad. Sci. pmid:6943955
Henson PM and Betz SJ Neutrophil and platelet interactions in "allergic" and inflammatory reactions: a role for acetyl glyceryl ether phosphorylcholine (platelet-activating factor). 1981 Kroc Found Ser pmid:6947075
Chignard M et al. [Platelet aggregation and platelet activating factor (author's transl)]. 1980 Oct-Dec J Pharmacol pmid:7206730
Camussi G et al. Platelet-activating factor (PAF), a mediator of platelet aggregation. Effect of corticosteroids on PAF-induced platelet aggregation. 1980 Oct-Dec Minerva Nefrol pmid:7254682
Suzuki K et al. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. 1980 Feb 1-15 Thromb. Res. pmid:6966083
Check WA A new age in asthma research: study of chemical mediators. 1980 Aug 22-29 JAMA pmid:6104737
Hanahan DJ et al. Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. 1980 J. Biol. Chem. pmid:7380824
Kirchmaier CM et al. A platelet stimulating fraction in human and animal tissues. 1980 Artery pmid:6971084